Mesodermal Progenitor Cells for Targeted Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current mesenchymal stem cell therapies for tissue repair face challenges due to inefficient migration of MSC subtypes to target tissues, requiring high cell doses that can lead to off-target side effects and volume-related issues, and are difficult to produce in large quantities from bone marrow.
Innovation Solution
Identification and isolation of a new class of progenitor cells of mesodermal lineage (PMLs) with specific marker expression patterns, capable of efficient migration and repair, produced from mononuclear cells such as peripheral blood, which express CD29, CD44, CD73, CD90, CD105, and CD271, but not CD14, CD34, and CD45, allowing for targeted tissue repair with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a mixture of MSC subtypes is used in therapy, then some therapeutic effects can be achieved, but migration efficiency to target tissue is poor requiring high cell doses
Solution Approach 1:
The patent extracts and isolates a specific subset of progenitor cells from the heterogeneous MSC population that possess enhanced migration capabilities. By separating cells based on specific marker expressions (CD29+, CD44+, CD73+, CD90+, CD105+, CD271+) and excluding others (CD14-, CD34-, CD45-), the invention creates a purified population with superior homing efficiency to target tissues, thereby resolving the contradiction between achieving therapeutic effects and maintaining poor migration efficiency.
Solution Approach 2:
The invention applies local quality by identifying and selecting cells with specific local characteristics (marker expression patterns) that are particularly suited for migration to target tissues. This selective approach ensures that only progenitor cells with the appropriate local quality attributes (high migration potential, low differentiation potential) are used, improving both migration efficiency and therapeutic reliability.
2Reliability
If high cell doses are used to compensate for poor migration, then therapeutic coverage is improved, but off-target side effects and volume-related side effects increase
Solution Approach 1:
By extracting and purifying the subset of progenitor cells with enhanced migration capabilities, the invention reduces the total cell dose required to achieve adequate therapeutic coverage. This purified population migrates more efficiently to target tissues, concentrating the therapeutic effect where needed and reducing off-target side effects and volume-related complications that arise from administering high cell doses.
3Quantity of substance
If MSCs are obtained from bone marrow, then stem cells can be sourced, but large amounts are difficult to obtain
Solution Approach 1:
The patent uses an intermediary approach by cultivating mononuclear cells from easily obtainable peripheral blood sources before differentiating them into the desired progenitor cell population. This intermediate step (culturing mononuclear cells) serves as a bridge between the easy-to-obtain blood sample and the final therapeutic cell product, enabling large-scale production that would be difficult to achieve directly from bone marrow.
Solution Approach 2:
The invention changes the source parameter from bone marrow to peripheral blood mononuclear cells, which are much easier to obtain in large quantities. By altering this fundamental parameter (cell source) and using a two-step process (culture mononuclear cells, then differentiate), the invention overcomes the limitation of difficult large-scale production from bone marrow while maintaining the ability to produce sufficient cell quantities for therapy.
Data Source
AI summary
The invention relates to progenitor cells of mesodermal lineage and their use in therapy.